Whole-life Investigation of Lishui Longevity

NCT07592962 | Recruiting DMC

• 2 other identifiers: 2026(I)164-01Lishui Key R&D Project
• Study Type: observational
• Target: 4,500
• Locations: 1 country
• Sites: 1

Brief Summary

1. 1.To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors.
2. 2.To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.

Conditions

Ischemic Stroke; Chronic Disease; Cardiovascular

Keywords

acute ischemic stroke; carotid artery stenosis; Hepatic fibrosis

Outcome Measures

Primary Outcomes (1)

• Prevalence rate of stroke and tumors

  A blood-based methylation pan-cancer assay was performed to screen for ten common malignancies, including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer, and pancreatic cancer. The prevalence of each cancer type was calculated as the number of confirmed positive cases divided by the total number of participants screened.

  From enrollment to the end of the 10-year follow-up period

Secondary Outcomes (1)

• Unilateral carotid artery stenosis rate

  From enrollment to the end of the 10-year follow-up period

Study Arms (3)

Cerebrovascular group

Participants in the cerebrovascular group receive head and neck magnetic resonance (MR) examination, transcranial Doppler (TCD) and cervical ultrasound. These examinations are used to screen cerebrovascular structural lesions, intracranial hemodynamic disorders and cervical atherosclerotic plaques, so as to identify early risk factors for stroke and cerebrovascular diseases.

Tumor Group

The tumor group undergoes methylation pan-cancer detection. This non-invasive and high-sensitivity assay is applied to screen aberrant methylation of tumor-related genes, covering ten common cancers including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer and pancreatic cancer, enabling early identification of potential malignant tumor risk in the population.

Epigenetic Age Group

The epigenetic age group accepts physiological age methylation detection combined with Vibration-Controlled Transient Elastography (VCTE). Methylation profiling of age-related CpG sites is used to evaluate individual physiological aging status, while VCTE is supplemented to assess liver elasticity and related metabolic characteristics.

Eligibility Criteria

• Age: 30 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population consists of 4,500 participants aged 30-80 years recruited from 10 urban and 10 rural sites in Lishui City using a cluster sampling method. Participants are randomly divided into three equal groups of 1,500 each, receiving different examination protocols. The collected data are further analyzed and grouped into cerebrovascular, tumor, and epigenetic age categories based on the respective test results.

You may qualify if:

• Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed informed consent.

You may not qualify if:

• Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.

Sponsors & Collaborators

• The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital: lead

Study Sites (1)

Lishui Central Hospital

Lishui, Zhejiang, 323000, China

RECRUITING

Related Publications (15)

• Pacinella G, Bona MM, Todaro F, Ciaccio AM, Daidone M, Tuttolomondo A. Tracing Inflammation in Ischemic Stroke: Biomarkers and Clinical Insight. Int J Mol Sci. 2025 Oct 8;26(19):9801. doi: 10.3390/ijms26199801.

  PMID: 41097065 BACKGROUND

• Wang J, Li Y, Qi L, Mamtilahun M, Liu C, Liu Z, Shi R, Wu S, Yang GY. Advanced rehabilitation in ischaemic stroke research. Stroke Vasc Neurol. 2024 Aug 27;9(4):328-343. doi: 10.1136/svn-2022-002285.

  PMID: 37788912 BACKGROUND

• Tao T, Liu M, Chen M, Luo Y, Wang C, Xu T, Jiang Y, Guo Y, Zhang JH. Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective. Pharmacol Ther. 2020 Dec;216:107695. doi: 10.1016/j.pharmthera.2020.107695. Epub 2020 Sep 28.

  PMID: 32998014 BACKGROUND

• Zhao D, Guallar E, Qiao Y, Knopman DS, Palatino M, Gottesman RF, Mosley TH Jr, Wasserman BA. Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities). Circulation. 2024 Sep 10;150(11):838-847. doi: 10.1161/CIRCULATIONAHA.123.067003. Epub 2024 Aug 1.

  PMID: 39087353 BACKGROUND

• Gilbertson RJ. Mapping cancer origins. Cell. 2011 Apr 1;145(1):25-9. doi: 10.1016/j.cell.2011.03.019.

  PMID: 21458665 BACKGROUND

• Paleari L. Personalized Assessment for Cancer Prevention, Detection, and Treatment. Int J Mol Sci. 2024 Jul 26;25(15):8140. doi: 10.3390/ijms25158140.

  PMID: 39125710 BACKGROUND

• Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578. Epub 2015 Dec 14.

  PMID: 26667886 BACKGROUND

• Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, Wang D, Wang Y, Feigin VL; NESS-China Investigators. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017 Feb 21;135(8):759-771. doi: 10.1161/CIRCULATIONAHA.116.025250. Epub 2017 Jan 4.

  PMID: 28052979 BACKGROUND

• Hachinski V, Einhaupl K, Ganten D, Alladi S, Brayne C, Stephan BCM, Sweeney MD, Zlokovic B, Iturria-Medina Y, Iadecola C, Nishimura N, Schaffer CB, Whitehead SN, Black SE, Ostergaard L, Wardlaw J, Greenberg S, Friberg L, Norrving B, Rowe B, Joanette Y, Hacke W, Kuller L, Dichgans M, Endres M, Khachaturian ZS. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement. 2019 Jul;15(7):961-984. doi: 10.1016/j.jalz.2019.06.001.

  PMID: 31327392 BACKGROUND

• Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, Wadley VG. Trajectory of Cognitive Decline After Incident Stroke. JAMA. 2015 Jul 7;314(1):41-51. doi: 10.1001/jama.2015.6968.

  PMID: 26151265 BACKGROUND

• Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hypponen E, Kuzma E, Llewellyn DJ. Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA. 2019 Aug 6;322(5):430-437. doi: 10.1001/jama.2019.9879.

  PMID: 31302669 BACKGROUND

• GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-480. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.

  PMID: 30879893 BACKGROUND

• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.

  PMID: 30496103 BACKGROUND

• Zhao Y, Zhang X, Chen X, Wei Y. Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review). Int J Mol Med. 2022 Feb;49(2):15. doi: 10.3892/ijmm.2021.5070. Epub 2021 Dec 8.

  PMID: 34878154 BACKGROUND

• Pan Y, Jing J, Cai X, Wang Y, Wang S, Meng X, Zeng C, Shi J, Ji J, Lin J, Lyu L, Zhang Z, Mei L, Li S, Li S, Zhu W, Li H, Wei T, Wang Y. PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)-a population-based prospective cohort study: rationale, design and baseline participant characteristics. Stroke Vasc Neurol. 2021 Mar;6(1):145-151. doi: 10.1136/svn-2020-000411. Epub 2020 Aug 30.

  PMID: 32863279 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral venous blood samples will be collected from participants and separated into serum, plasma, and leukocyte components. The leukocyte fraction will be used for DNA extraction and subsequent methylation molecular analysis. All samples will be stored in a dedicated biobank at Lishui Central Hospital.

MeSH Terms

Conditions

Ischemic Stroke; Chronic Disease; Carotid Stenosis; Liver Cirrhosis

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Carotid Artery Diseases; Arterial Occlusive Diseases; Liver Diseases; Digestive System Diseases; Fibrosis

Study Officials

• Jiansong Ji, PhD

  The Central Hospital of Lishui City

  STUDY CHAIR

Central Study Contacts

Jingping Sun, PhD

CONTACT

86-18504713450; lszxyysunjingping@yeah.net

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 12, 2026
• First Posted: May 18, 2026
• Study Start: May 18, 2026
• Primary Completion (Estimated): May 31, 2036
• Study Completion (Estimated): May 31, 2036
• Last Updated: May 18, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)